Eur Rev Med Pharmacol Sci 2022; 26 (7): 2305-2312
DOI: 10.26355/eurrev_202204_28460

Inhibition of microRNA-543 alleviates sepsis-induced acute kidney injury via targeting Bcl-2

W.-Q. Zhang, H.-J. Wang, Y.-Z. Li, X.-F. Du, X.-L. Hao, H.-M. Jiang, L.-H. Yang

Department of Critical Care Medicine, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China. vikyz1@163.com


OBJECTIVE: Sepsis has a high morbidity and mortality and is prone to cause acute kidney injury (AKI). Here, we aimed to demonstrate the function and molecular mechanism of microRNA-543 (miR-543) in septic AKI.

MATERIALS AND METHODS: MiR-543 inhibitor or NC was transfected into LPS-treated HK-2 cells to observe lipopolysaccharide (LPS)-induced inflammation and apoptosis. The detection of inflammation and apoptosis of HK-2 cells relies on Western blot, quantitative Reverse-Transcription Polymerase Chain Reaction (qRT-PCR), enzyme-linked immunosorbent assay (ELISA), Cell Counting Kit-8 (CCK-8) assay, flow cytometry, and terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) staining.

RESULTS: MiR-543 expression was increased in LPS-treated HK-2 cells. By transfecting miR-543 inhibitor into HK-2 cells, miR-543 expression was dramatically reduced. The downregulation of miR-543 remarkably inhibited the inflammation and apoptosis, which was manifested by the reduction of inflammatory cytokines (TNF-α, IL-6, IL-1β), the reversal of apoptosis-related proteins expression (Bcl-1, Bax), the increase of cell viability and the decrease of the proportion of apoptotic cells. The result of Luciferase activity assay demonstrated that miR-543 directly targets Bcl-2.

CONCLUSIONS: MiR-543 expression was increased in LPS-treated HK-2 cells, and silencing miR-543 could inhibit LPS-induced inflammation and apoptosis in HK-2 cells via targeting Bcl-2.

Free PDF Download

To cite this article

W.-Q. Zhang, H.-J. Wang, Y.-Z. Li, X.-F. Du, X.-L. Hao, H.-M. Jiang, L.-H. Yang
Inhibition of microRNA-543 alleviates sepsis-induced acute kidney injury via targeting Bcl-2

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 7
Pages: 2305-2312
DOI: 10.26355/eurrev_202204_28460